| 项目编号 |
PRJCA059358 |
| 项目标题 |
Combination therapy of colistin and bacteriocins eradicates multidrug-resistant Acinetobacter baumannii and prevents resistance selection |
| 涉及领域 |
Medical |
| 数据类型 |
Whole genome sequencing
|
| 物种名称 |
|
| 描述信息 |
Acinetobacter baumannii is a multidrug-resistant nosocomial pathogen causing infections that are difficult to treat with conventional antibiotics. Considering this challenge, bacteriocins are being regarded as complementary approaches to antibiotics. Here, we have shown that two bacteriocins produced by Gram-positive bacteria inhibit the growth of multidrug-resistant clinical isolates of A. baumannii, albeit at high concentrations. In vitro characterization revealed that they permeabilize phospholipidic vesicles, suggesting their potential to enhance the efficacy of antibiotics disrupting cell envelope integrity. Low doses of these bacteriocins potentiate low doses of colistin or imipenem, two antibiotics disrupting the cell envelope by different mechanisms, thereby enabling a substantial reduction in survival by compromising the inner membrane. Importantly, these combinations hinder both colistin tolerance and emergence of colistin-resistant mutants, which are rapidly selected during colistin treatment, and partially resensitizes a highly colistin-resistant clinical isolate. These findings illustrate the efficacy of rationally designed combination treatments involving antibiotics and bacteriocins. |
| 样品范围 |
Multiisolate |
| 发布日期 |
2026-03-04 |
| 项目资金来源 |
| 机构 |
项目类型 |
授权项目ID |
授权项目名称 |
| No funding support
|
|
|
|
|
|
| 本项目在其他数据库系统中的项目序列号 |
| 项目序列号 |
数据库名称 |
| PRJNA1270763
|
NCBI
|
|
|
| 项目相关网站链接 |
|
| 提交者 |
Thomas
zur nedden (thomas.zur.nedden@ulb.be)
|
| 提交单位 |
Universite libre de Bruxelles |
| 提交日期 |
2026-03-04 |
